ROBO2 and acute myeloid leukemia: It was found that AML patients were generally high expressers of ROBO1, high expression being noted in 72.15% of the AML group compared to 4.35% of controls (p < 0.0001), and of ROBO2, with 82.28% of the AML group expressing high ROBO2 compared to 39.13% of controls (p < 0.001).